Accessibility Menu
Alkermes Plc Stock Quote

Alkermes Plc (NASDAQ: ALKS)

$31.69
(0.8%)
+0.24
Price as of October 22, 2025, 11:38 a.m. ET

KEY DATA POINTS

Current Price
$31.63
Daily Change
(0.8%) +$0.24
Day's Range
$29.95 - $31.79
Previous Close
$31.45
Open
$29.97
Beta
0.61
Volume
89,174
Average Volume
1,912,310
Market Cap
5.2B
Market Cap / Employee
$31.45M
52wk Range
$25.17 - $36.45
Revenue
-
Gross Margin
0.85%
Dividend Yield
N/A
EPS
$2.08
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Alkermes Plc Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ALKS+13.5%+95.85%+14.39%+481%
S&P+15.06%+95.03%+14.29%+1,665%

Alkermes Plc Company Info

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

News & Analysis

The Fool has written over 100 articles on Alkermes Plc.

Financial Health

General

Q2 2025YOY Change
Revenue$390.66M-2.1%
Gross Profit$339.70M1.0%
Gross Margin86.96%2.7%
Market Cap$4.72B15.7%
Market Cap / Employee$2.62M0.0%
Employees1.8K-14.3%
Net Income$87.10M-8.0%
EBITDA$100.80M-13.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$521.20M-2.6%
Accounts Receivable$356.33M-3.7%
Inventory191.9-1.4%

Liabilities

Q2 2025YOY Change
Long Term Debt$66.22M-81.6%
Short Term Debt$6.46M-28.3%

Ratios

Q2 2025YOY Change
Return On Assets15.61%0.0%
Return On Invested Capital8.85%7.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$137.19M-1.2%
Operating Free Cash Flow$150.20M2.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings14.2613.1915.7213.73-3.81%
Price to Book3.503.603.663.12-3.98%
Price to Sales3.113.083.683.2017.10%
Price to Tangible Book Value3.753.853.883.30-5.14%
Price to Free Cash Flow TTM14.8311.8111.5710.04-20.30%
Enterprise Value to EBITDA36.9824.27224.4738.4323.98%
Free Cash Flow Yield6.7%8.5%8.6%10.0%25.48%
Return on Equity29.2%27.9%25.7%23.9%-10.24%
Total Debt$366.00M$75.54M$74.10M$72.68M-80.25%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.